CT041 uses a CAR structure with a humanized scFv specific to CLDN18.2, a CD8α hinge region, and a CD28 costimulatory domain, enhancing its specificity and efficacy.58,59 Although primarily tested in advanced gastric and pancreatic cancers, CT041's success in targeting gastrointestinal tumors suggests potential applicability in CRC. Here, CD28 is linked to colorectal carcinoma.